Patents by Inventor Gerald Scott Barden HORAN

Gerald Scott Barden HORAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING SMAD7 ANTISENSE OLIGONUCLEOTIDES BASED ON BIOMARKER EXPRESSION
    Publication number: 20200237801
    Abstract: Described herein are methods of treating inflammatory bowel disease (IBD) in a patient having IBD using SMAD7 antisense oligonucleotides.
    Type: Application
    Filed: September 30, 2016
    Publication date: July 30, 2020
    Inventors: Salvatore BELLINVIA, Giovanni MONTELEONE, Gerald Scott BARDEN HORAN
  • Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
    Patent number: 10197579
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: February 5, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Gerald Scott Barden Horan, Ying Ye
  • TLR MODULATORS AND METHODS OF USE
    Publication number: 20180289692
    Abstract: Described herein are combinations comprising a SMAD7 oligonucleotide and a Toll-like receptor (TLR) modulator. Methods for using such combinations to treat disease conditions, including inflammatory disorders, such as inflammatory bowel disease (IBD), are also provided herein.
    Type: Application
    Filed: September 30, 2016
    Publication date: October 11, 2018
    Inventor: Gerald Scott Barden HORAN
  • METHODS FOR MEASUREMENT OF INHIBITION OF C-JUN N-TERMINAL KINASE IN SKIN
    Publication number: 20170045531
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Application
    Filed: October 27, 2016
    Publication date: February 16, 2017
    Inventors: Gerald Scott Barden HORAN, Ying YE
  • Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
    Patent number: 9513297
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyzes allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: December 6, 2016
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Gerald Scott Barden Horan, Ying Ye
  • METHODS FOR MEASUREMENT OF INHIBITION OF C-JUN N-TERMINAL KINASE IN SKIN
    Publication number: 20160169908
    Abstract: Provided herein are methods for evaluating the effect of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof in a patient with an assay based on UVB-irradiation and phosphorylated c-Jun expression. The analyses allow for evaluation of dose-response and identification of patient populations who are sensitive to 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide or a pharmaceutically acceptable stereoisomer, tautomer, solid form, polymorph, salt, hydrate, clathrate, or solvate thereof.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Inventors: Gerald Scott Barden HORAN, Ying YE